glp-1 obesity drug news october 21 2025 New Pill Foundayo (Orforglipron) Gets FDA Approval for How to Invest in GLP-1

Excess abdominal skin Skin that has been significantly stretched by pregnancy, major weight loss or both loses its elasticity permanently

It is becoming increasingly obvious that treating obesity also requires a multimodal approach that combines lifestyle interventions, pharmacotherapy, and bariatric surgery to achieve the tailored weight loss and metabolism goals needed for long-term health gain

Compared with other growth hormone releasing peptides such as GHRP, Ipamorelin has unique advantages

In multiple sclerosis models, GLP-1 receptor activation reduces pathogenic Th1 and Th17 cell activity, inhibits microglial activation (the brain equivalent of macrophage inflammation), and may enhance remyelination processes